TickerHumSide-by-side comparison
AbbVie vs Eli Lilly and
As of Nov 11, 2026, P/E is 50.8x for AbbVie vs 46.7x for Eli Lilly and; P/S is 7.9x for AbbVie vs 15.6x for Eli Lilly and; revenue growth is 10.7% for AbbVie vs 45.5% for Eli Lilly and; net margin is 15.7% for AbbVie vs 31.9% for Eli Lilly and.
What stands out
- Eli Lilly and is growing revenue faster: 45.5% vs 10.7% for AbbVie.
Key metrics
| Metric | ABBV | LLY |
|---|---|---|
| Price | $294.88 | $1,437.76 |
| Market cap | $521.23B | $1.35T |
| P/E | 50.8x (#2) | 46.7x (#1) |
| P/S | 7.9x (#1) | 15.6x (#2) |
| Revenue growth | 10.7% (#2) | 45.5% (#1) |
| Operating margin | 32.2% (#1) | — |
| Net margin | 15.7% (#2) | 31.9% (#1) |
| Debt / equity | — | 1.17 (#1) |
| 1-year return | +26.4% (#2) | +41.3% (#1) |
| Research score | 62/100 (#2) | 70/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- AbbVie Inc. (ABBV) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General